Innate Immunity
11
1
1
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
9.1%
1 terminated out of 11 trials
87.5%
+1.0% vs benchmark
9%
1 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (11)
Innate Immune Response During Community Acquired Pneumonia
Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848)
Bovine Colostrum Supplementation in Athletes
Implication of UNconventionaL T Lymphocytes in Cystic Fibrosis (UNLOCk)
Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau
Immune Cells Phenotypes During COVID-19
Immunity Modification of Full Term Infants According to the Type of Feeding and Mode of Delivery
Immune Responses to Two Experimental HIV Vaccines in Healthy Adults
Passive Smoking and LL-37 in Children
Immunity Modification of Full Term Infants According to the Type of Feeding and Mode of Delivery
Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects